13F Data
13F filer · CIK 2006045

SymBiosis Capital Partners, LLC

BENTONVILLE, AR · filing since Q4 2025 · last filing May 12, 2026
Reported value
$52.8M
$-56.7M vs prior
Positions
6
New / sold out
1 / 6
Added / reduced
0 / 3
Turnover
6.7%
buys $5.4M · sells $67.4M
Top-10 weight
100.0%

Biggest buys vs Q4 2025

ChangeSecurityShares changeChange %Est. trade value
NewWave Life Sciences Ltd.+750,000–+$5.4M

Biggest sells vs Q4 2025

ChangeSecurityShares changeChange %Est. trade value
Sold outVerastem Inc-2,000,000-100.0%$-15.4M
Sold outAldeyra Therapeutics Inc-2,555,000-100.0%$-13.2M
Sold outPrecigen Inc-3,000,000-100.0%$-12.5M
Sold outNuvation Bio Inc-1,250,000-100.0%$-11.2M
Sold outAardvark Therapeutics, Inc.-476,595-100.0%$-6.3M
Sold outGeneration Bio Co-665,000-100.0%$-3.8M
ReducedRani Therapeutics Holdings, Inc.-2,632,415-41.8%$-1.9M
ReducedClene Nanomedicine Inc.-339,401-44.0%$-1.7M
ReducedInventiva S.A.-246,000-9.5%$-1.4M

Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.

Reported value by quarter

Q4 2025: $109.5MQ1 2026: $52.8M
Q4 2025Q1 2026

Holdings · Q1 2026

#SecuritySharesValueWeight
1Evommune, Inc.COM SHS1,280,778$29.4M55.80%
2Inventiva S.A.ADS2,354,000$13.1M24.76%
3Wave Life Sciences Ltd.SHS750,000$5.4M10.30%
4Rani Therapeutics Holdings, Inc.COM CL A3,667,585$2.7M5.11%
5Clene Nanomedicine Inc.COM NEW431,094$2.1M4.03%
6Surrozen, Inc.*W EXP 08/01/203150,000$2.4K0.00%